옵션 체인은 다양한 행사가격과 만기일에 대한 Intellia Therapeutics의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Intellia Therapeutics에 대한 시장 심리를 평가합니다..

Intellia Therapeutics (NASDAQ:NTLA) 주식, 옵션 체인

Intellia Therapeutics

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Equities

News

Markets

ETFs

ADPT

ARKG

ARKK

ILMN

NTLA

RXRX

캐시 우드가 이끄는 아크 인베스트는 금요일에 리커젼 파마슈티컬스(NASDAQ:RXRX), 일루미나(NASDAQ:ILMN), 인텔리아 테라퓨틱스(NASDAQ:NTLA), 클라우드플레어(NYSE:NET) 그리고 어댑티브 바이오테크놀로지스(NASDAQ:ADPT)의 주요 회사들에서 상당한 거래를 진행했다.

캐시 우드의 아크 인베스트, 인력의 4분의 1 이상을 해고한 인텔리아 테라퓨틱스에 투자

Biotech

Health Care

BEAM

CDNA

CRSP

TWST

VCYT

아크 인베스트의 CEO인 캐시 우드는 인공지능, 유전자 염기서열(시퀀싱) 분석, 유전자 편집 기술의 교차점에서 전례 없는 잠재력을 발견하고 바이오 분야에 투자를 강화하고 있다.

캐시 우드, 바이오 분야에서 4천억 달러 기회 전망

CPRI

MNPR

TSLA

미국 주식 시장은 목요일에 혼조세를 보였다. 나스닥 종합지수는 130포인트 이상 상승한 반면, 다우존스 지수는 0.3% 하락하여 42,374.36으로 마감되었다. S&amp;P 500 지수도 0.2% 상승하여 5,809.86으로 마감했다.

목요일 주목받은 주식: 모노파 테라퓨틱스, 인텔리아 테라퓨틱스, 카프리, 웨스턴 디지털 및 테슬라

Intellia Therapeutics, Inc. - Common Stock

Intellia Therapeutics Inc

Ratings for Corteva (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTVA#NYSE">CTVA</a>) were provided by 12 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">6</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Corteva and provided 12-month price targets. The average target is $68.58, accompanied by a high estimate of $73.00 and a low estimate of $62.00. This current average has increased by 2.36% from the previous average price target of $67.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1737486060_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
A comprehensive examination of how financial experts perceive Corteva is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Benjamin Theurer</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$64.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Joshua Spector</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$73.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>Aleksey Yefremov</td>
<td>Keybanc</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$68.00</td>
<td>$69.00</td>
</tr>
<tr>
<td>Arun Viswanathan</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$73.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Patrick Cunningham</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$69.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Aleksey Yefremov</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$69.00</td>
<td>$66.00</td>
</tr>
<tr>
<td>Richard Garchitorena</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$67.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Steve Byrne</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$69.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>Arun Viswanathan</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$68.00</td>
<td>$69.00</td>
</tr>
<tr>
<td>Benjamin Theurer</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$62.00</td>
<td>$58.00</td>
</tr>
<tr>
<td>Kristen Owen</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$70.00</td>
<td>$69.00</td>
</tr>
<tr>
<td>Joshua Spector</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$71.00</td>
<td>$67.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Corteva. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Corteva compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Corteva's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
To gain a panoramic view of Corteva's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/CTVA/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Corteva analyst ratings.</a>
<h2>Get to Know Corteva Better</h2>
Corteva is an agricultural inputs pure play that was formed in 2019 when it was spun off from DowDuPont. The company is a leader in the development of new seed and crop protection products. Seeds generate the majority of profits with the remainder coming from crop protection products. Corteva operates globally, but around half of revenue comes from North America.
<h3>Corteva: Delving into Financials</h3>
Market Capitalization: Exceeding industry standards, the company's market capitalization places it above industry average in size relative to peers. This emphasizes its significant scale and robust market position.
Negative Revenue Trend: Examining Corteva's financials over 3 months reveals challenges. As of 30 September, 2024, the company experienced a decline of approximately -10.19% in revenue growth, reflecting a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Materials sector.
Net Margin: Corteva's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of -22.53%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -2.1%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Corteva's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -1.26%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.23.
<h2>Analyst Ratings: Simplified</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

CTVA

12 Analysts Have This To Say About Corteva

WIIM

ServiceNow shares are trading higher after JMP Securities raised its price target on the stock from $1000 to $1300.

Throughout the last three months, 12 analysts have evaluated Best Buy Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBY#NYSE">BBY</a>), offering a diverse set of opinions from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
In the assessment of 12-month price targets, analysts unveil insights for Best Buy Co, presenting an average target of $102.5, a high estimate of $117.00, and a low estimate of $89.00. Highlighting a 5.02% decrease, the current average has fallen from the previous average price target of $107.92. 
<img src="https://www.benzinga.com/files/images/story/2025/1737486053_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Best Buy Co. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Simeon Gutman</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$100.00</td>
<td>$105.00</td>
</tr>
<tr>
<td>Seth Sigman</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$89.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Anthony Chukumba</td>
<td>Loop Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$100.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Steven Forbes</td>
<td>Guggenheim</td>
<td>Lowers</td>
<td>Buy</td>
<td>$105.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Zachary Fadem</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$89.00</td>
<td>$95.00</td>
</tr>
<tr>
<td>Michael Lasser</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$115.00</td>
<td>$123.00</td>
</tr>
<tr>
<td>Scot Ciccarelli</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$95.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>Steven Zaccone</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$101.00</td>
<td>$109.00</td>
</tr>
<tr>
<td>Anthony Chukumba</td>
<td>Loop Capital</td>
<td>Lowers</td>
<td>Buy</td>
<td>$100.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Joseph Feldman</td>
<td>Telsey Advisory Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$110.00</td>
<td>$115.00</td>
</tr>
<tr>
<td>Christopher Horvers</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$117.00</td>
<td>$111.00</td>
</tr>
<tr>
<td>Steven Zaccone</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$109.00</td>
<td>$115.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Best Buy Co. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Best Buy Co compared to the broader market.</li>
<li>Price Targets: Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
Capture valuable insights into Best Buy Co's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/BBY/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Best Buy Co analyst ratings.</a>
<h2>About Best Buy Co</h2>
With $43.5 billion in consolidated 2023 sales, Best Buy is the largest pure-play consumer electronics retailer in the US, boasting roughly 8.3% share of the North American market and north of 33% share of offline sales in the region, per our calculations, CTA, and Euromonitor data. The firm generates the bulk of its sales in-store, with mobile phones and tablets, computers, and appliances representing its three largest categories. Recent investments in e-commerce fulfillment, accelerated by the covid-19 pandemic, have seen the US e-commerce channel roughly double from prepandemic levels, with management estimating that it will represent a mid-30% proportion of sales moving forward.
<h3>Best Buy Co: A Financial Overview</h3>
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: Best Buy Co's revenue growth over a period of 3 months has faced challenges. As of 31 October, 2024, the company experienced a revenue decline of approximately -3.19%. This indicates a decrease in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Consumer Discretionary sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 2.89%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Best Buy Co's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 8.82% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Best Buy Co's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 1.67% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Best Buy Co's debt-to-equity ratio surpasses industry norms, standing at 1.32. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>The Significance of Analyst Ratings Explained</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What 12 Analyst Ratings Have To Say About Best Buy Co

Providing a diverse range of perspectives from bullish to bearish, 10 analysts have published ratings on Penumbra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PEN#NYSE">PEN</a>) in the last three months.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">5</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $271.1, a high estimate of $323.00, and a low estimate of $235.00. Surpassing the previous average price target of $230.75, the current average has increased by 17.49%.
<img src="https://www.benzinga.com/files/images/story/2025/1737486036_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The perception of Penumbra by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Priya Sachdeva</td>
<td>UBS</td>
<td>Announces</td>
<td>Buy</td>
<td>$305.00</td>
<td>-</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$285.00</td>
<td>$240.00</td>
</tr>
<tr>
<td>Steve Lichtman</td>
<td>Oppenheimer</td>
<td>Announces</td>
<td>Outperform</td>
<td>$275.00</td>
<td>-</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$245.00</td>
<td>$220.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$275.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Jason Mills</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$323.00</td>
<td>$260.00</td>
</tr>
<tr>
<td>Ryan Zimmerman</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$270.00</td>
<td>$232.00</td>
</tr>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$250.00</td>
<td>$235.00</td>
</tr>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$235.00</td>
<td>$225.00</td>
</tr>
<tr>
<td>David Rescott</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$248.00</td>
<td>$244.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Penumbra. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Penumbra compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Penumbra's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Penumbra's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PEN/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Penumbra analyst ratings.</a>
<h2>About Penumbra</h2>
Penumbra Inc develops and manufactures medical devices for the neurovascular and peripheral vascular markets. Its products are sold to hospitals and are developed for use by specialist physicians. The neurovascular product category contributes to the majority of revenue. Within the neurovascular business, the firm offers products for neurovascular access, ischemic stroke, neurovascular embolization, and neurosurgical tool markets. In the peripheral vascular business, the firm sells devices related to peripheral embolization and peripheral thrombectomy. Penumbra generates the majority of its revenue in the United States.
<h3>Penumbra: Financial Performance Dissected</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Positive Revenue Trend: Examining Penumbra's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 11.11% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Penumbra's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 9.81%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Penumbra's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 2.61%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 1.96%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.21.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

10 Analysts Assess Penumbra: What You Need To Know

Providing a diverse range of perspectives from bullish to bearish, 17 analysts have published ratings on Apellis Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLS#NASDAQ">APLS</a>) in the last three months.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">6</td>
<td align="right">2</td>
<td align="right">9</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">5</td>
<td align="right">2</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $39.71, a high estimate of $60.00, and a low estimate of $24.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 26.46%. 
<img src="https://www.benzinga.com/files/images/story/2025/1737486028_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The analysis of recent analyst actions sheds light on the perception of Apellis Pharmaceuticals by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$26.00</td>
<td>$26.00</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$57.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Salveen Richter</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Neutral</td>
<td>$36.00</td>
<td>-</td>
</tr>
<tr>
<td>Judah Frommer</td>
<td>Morgan Stanley</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$31.00</td>
<td>-</td>
</tr>
<tr>
<td>Colleen Kusy</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$55.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Yigal Nochomovitz</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$51.00</td>
<td>$63.00</td>
</tr>
<tr>
<td>Salveen Richter</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$36.00</td>
<td>$71.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$24.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Greg Harrison</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$30.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Derek Archila</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$30.00</td>
<td>$43.00</td>
</tr>
<tr>
<td>Justin Kim</td>
<td>Oppenheimer</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$40.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Biren Amin</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$32.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Douglas Tsao</td>
<td>HC Wainwright &amp; Co.</td>
<td>Lowers</td>
<td>Buy</td>
<td>$57.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>Tazeen Ahmad</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$47.00</td>
<td>$61.00</td>
</tr>
<tr>
<td>Joseph Stringer</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$60.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Luca Issi</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Sector Perform</td>
<td>$25.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$38.00</td>
<td>$39.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Apellis Pharmaceuticals. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Apellis Pharmaceuticals compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Apellis Pharmaceuticals's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Apellis Pharmaceuticals's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/APLS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Apellis Pharmaceuticals analyst ratings.</a>
<h2>About Apellis Pharmaceuticals</h2>
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade.
<h3>Apellis Pharmaceuticals's Economic Impact: An Analysis</h3>
Market Capitalization: Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.
Positive Revenue Trend: Examining Apellis Pharmaceuticals's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 78.29% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -29.19%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Apellis Pharmaceuticals's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of -22.91%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Apellis Pharmaceuticals's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -6.36%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Apellis Pharmaceuticals's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.98, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>What Are Analyst Ratings?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

APLS

Analyst Expectations For Apellis Pharmaceuticals's Future

Truist Finl's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFC#NYSE">TFC</a>) short percent of float has fallen 20.92% since its last report. The company recently reported that it has 16.10 million shares sold short, which is 1.21% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.46 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Truist Finl Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737486024_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Truist Finl has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing Truist Finl's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Truist Finl's peer group average for short interest as a percentage of float is 3.54%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

(TFC) - Analyzing Truist Finl's Short Interest

In the last three months, 7 analysts have published ratings on Revvity (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RVTY#NYSE">RVTY</a>), offering a diverse range of perspectives from bullish to bearish.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $140.86, a high estimate of $146.00, and a low estimate of $135.00. Observing a downward trend, the current average is 1.38% lower than the prior average price target of $142.83. 
<img src="https://www.benzinga.com/files/images/story/2025/1737486021_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The analysis of recent analyst actions sheds light on the perception of Revvity by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Andrew Cooper</td>
<td>Raymond James</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$140.00</td>
<td>$146.00</td>
</tr>
<tr>
<td>Derik De Bruin</td>
<td>B of A Securities</td>
<td>Announces</td>
<td>Buy</td>
<td>$138.00</td>
<td>-</td>
</tr>
<tr>
<td>Luke Sergott</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$135.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Dan Brennan</td>
<td>TD Cowen</td>
<td>Raises</td>
<td>Buy</td>
<td>$144.00</td>
<td>$141.00</td>
</tr>
<tr>
<td>Eve Burstein</td>
<td>Bernstein</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$145.00</td>
<td>$150.00</td>
</tr>
<tr>
<td>Andrew Cooper</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$146.00</td>
<td>$144.00</td>
</tr>
<tr>
<td>Catherine Ramsey</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$138.00</td>
<td>$136.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Revvity. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Revvity compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Revvity's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Revvity's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/RVTY/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Revvity analyst ratings.</a>
<h2>Delving into Revvity's Background</h2>
Revvity provides instruments, tests, services, and software solutions to the pharmaceutical, biomedical, chemical, environmental, and general industrial markets. The company operates in two segments. First, its diagnostics segment includes immunodiagnostics, reproductive health, and applied genomics. Second, its discovery and analytical solutions is composed of life science, industrial, environmental, and food applications. Revvity offers products and services ranging from genetic screening and environmental analytical tools to informatics and enterprise software.
<h3>Breaking Down Revvity's Financial Performance</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Revvity's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 1.98% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Revvity's net margin is impressive, surpassing industry averages. With a net margin of 13.8%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Revvity's ROE excels beyond industry benchmarks, reaching 1.2%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): Revvity's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 0.72%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Revvity's debt-to-equity ratio is below the industry average at 0.42, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

RVTY

Forecasting The Future: 7 Analyst Projections For Revvity

XPeng's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>) short percent of float has fallen 9.76% since its last report. The company recently reported that it has 44.60 million shares sold short, which is 5.92% of all regular shares that are available for trading. Based on its trading volume, it would take traders 6.57 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>XPeng Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737486018_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for XPeng has declined since its last report. This does not mean that the stock is going to rise in the near-term but traders should be aware that less shares are being shorted.
<h3>Comparing XPeng's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, XPeng's peer group average for short interest as a percentage of float is 8.90%, which means the company has less short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

XPEV

Looking Into XPeng's Recent Short Interest

Hamilton Lane's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLNE#NYSE">HLNE</a>) short percent of float has risen 66.67% since its last report. The company recently reported that it has 1.60 million shares sold short, which is 4.05% of all regular shares that are available for trading. Based on its trading volume, it would take traders 2.53 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Hamilton Lane Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1737486013_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Hamilton Lane has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Hamilton Lane's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Hamilton Lane's peer group average for short interest as a percentage of float is 3.24%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

HLNE

How Is The Market Feeling About Hamilton Lane?

In the latest quarter, 5 analysts provided ratings for Axos Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AX#NYSE">AX</a>), showcasing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $84.0, a high estimate of $91.00, and a low estimate of $74.00. Witnessing a positive shift, the current average has risen by 5.53% from the previous average price target of $79.60.
<img src="https://www.benzinga.com/files/images/story/2025/1737486012_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The standing of Axos Financial among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kyle Peterson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$85.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Kyle Peterson</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$85.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Kelly Motta</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$91.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>Kelly Motta</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$74.00</td>
<td>$72.00</td>
</tr>
<tr>
<td>Kyle Peterson</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$85.00</td>
<td>$82.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Axos Financial. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Axos Financial compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Axos Financial's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Axos Financial's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/AX/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Axos Financial analyst ratings.</a>
<h2>Delving into Axos Financial's Background</h2>
Axos Financial Inc is a bank holding company that operates through its bank subsidiary, BofI Federal Bank, a nationwide bank that provides financing for single and multifamily residential properties, small to medium-size businesses in certain sectors, and selected specialty finance receivables. Its operating segments are banking business segment and securities business segment . The bank distributed its products through a wide range of retail distribution channels, including only banking brands, affinity groups, and sales teams, among others. The majority of the bank's mortgage exposure is titled toward the state of California, particularly its southern region. Net interest income is a majority of the bank's revenue.
<h3>Axos Financial: Financial Performance Dissected</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Axos Financial's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 30.91%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Financials sector.
Net Margin: Axos Financial's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 35.51%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 4.78%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 0.48%, the company showcases effective utilization of assets.
Debt Management: Axos Financial's debt-to-equity ratio is below the industry average. With a ratio of 0.17, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>How Are Analyst Ratings Determined?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Axos Financial Stock: A Deep Dive Into Analyst Perspectives (5 Ratings)

Vistra shares are trading higher after Evercore ISI reinstated coverage with an Outperform rating.

Options

FUBO

FuboTV Option Alert: Feb 14 $4 Calls at the Ask: 1046 @ $0.24 vs 780 OI; Earnings 2/28 Before Open [est] Ref=$3.7212

CRWD

CrowdStrike shares are trading higher after the company announced it's partnering with Cognizant to enhance global cybersecurity enterprise systems. Also, Scotiabank raised its price target on the stock from $300 to $370.

Evercore ISI Group analyst Durgesh Chopra reinstates Vistra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VST#NYSE">VST</a>) with a Outperform and announces $202 price target.

Price Target

Initiation

Evercore ISI Group Reinstates Outperform on Vistra, Announces $202 Price Target

Scotiabank analyst Patrick Colville maintains N-able (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NABL#NYSE">NABL</a>) with a Sector Perform and lowers the price target from $11.2 to $11.

NABL

Scotiabank Maintains Sector Perform on N-able, Lowers Price Target to $11

PNC Financial Services Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PNC#NYSE">PNC</a>) reported&nbsp;fourth-quarter results last week. Revenue increased 4% year-over-year to&nbsp;$5.57&nbsp;billion, beating the&nbsp;consensus of&nbsp;$5.50 billion. Revenue growth was led by higher net <a target="_blank" href="https://www.benzinga.com/news/buybacks/25/01/43025676/pnc-financial-q4-earnings-credit-losses-provision-dips-forecasts-sequential-fall-in-q1-revenue-and-loans" rel="noreferrer noopener">interest income and noninterest income.</a>
Goldman Sachs analyst Richard Ramsden reiterated the Neutral rating on the stock, with a price forecast of $203.
The analyst notes that with better-than-expected results and largely in-line guidance, there is potential for upside in net interest income, driven by loan growth, which could accelerate in the second half of 2025, and a further steepening of the yield curve, benefiting fixed asset repricing and supporting NII growth through 2026.
The analyst also expects the company to achieve solid operating leverage of around 400 basis points in 2025, with expenses growing about 1.5% year-over-year.
Additionally, the company continues to build capital, with its CET1 ratio reaching 10.5% (9.2% adjusted for AOCI), well above the updated regulatory minimum of 7.0%.
Given this excess capital, the analyst anticipates the company will increase its share buybacks, starting from the $200 million level in the fourth quarter of 2024, once there is more clarity on regulatory capital requirements.
Based on the latest results and guidance, the analyst slightly lowers 2026 earnings per share estimates by 1%, with new EPS targets of $15.05 for 2025 and $17.09 for 2026 (from $15.01, and $17.32 respectively).
The analyst also introduces a 2027 EPS estimate of $18.76, and the 2025 P/E target remains unchanged at 13.5x.
Price Action: PNC shares are trading lower by 0.33% to $197.87 at last check Tuesday.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/01/43097430/trumps-drill-baby-drill-era-begins-oil-prices-tumble-us-energy-stocks-edge-up" target="_blank" rel="noreferrer noopener">Trump's ‘Drill, Baby, Drill' Era Begins: Oil Prices Tumble, US Energy Stocks Edge Up</a></li>
</ul>

Analyst Color

Reiteration

General

PNC Financial Positioned For Strong Loan Expansion And Yield Curve Benefits, Analyst Predicts Net Interest Income Growth Through 2026

Taiwan Semiconductor Manufacturing shares are trading higher after the company announced it received $1.5 billion in U.S. chip subsidies.

Last month, two European quants, one working for Robeco and the other for Allianz, published a paper asking (and answering) whether formulaic investing is possible. Marcel Schwartz of Allianz and Matthias X. Hanauer of Robeco are also associated with the Technical University of Munich.
The pair studied four formulas, including a conservative low-volatility strategy, The Acquirers Multiple, The Piotroski F-Score, and Joel Greenblatt&#8217;s Magic Formula.
Interestingly, people associated with developing these formulas, such as Tobias Carlisle of Acquirers Funds and Wes Gray and Jack Vogel of Alpha Architect, also consulted on the paper.
To make a long story short, all four formulas delivered excess returns.
I am a huge fan of formula investing and have used the Acquirers Multiple and the F-Score strategies successfully over the years.
To me, they are both extensions of Ben Graham&#8217;s original value-investing and margin-of-safety theories.
I am quite familiar with the Magic Formula, although I have not used it as much as I probably should have.
If the Acquirers Multiple and F-Score models are descendants of Ben Graham, the Magic Formula is the reincarnation of a young Charlie Munger. Greenblatt&#8217;s formula helps identify companies that are earning high returns on the capital used to build and run the business and trading at bargain prices.
I decided to run a survey to find stocks that fit the Magic Formula definition in today&#8217;s overheated market.
I also added some features that increase my comfort level with owning these bargain issues.
The broader market may face tough sledding going forward as large-cap stocks are priced for perfection in an imperfect world.
Because of that, I want to collect a dividend.
Dividends, once paid, cannot be taken away.
Finally, I am always aware that it is unlikely that one will beat the market by doing what everyone else does.
I want my stocks to be under-owned by institutions.
If the company keeps earning high returns on capital, the big money funds will eventually pile into the stock, and their buying pressure will send the prices soaring.
United-Guardian (Ticker: UG) makes the list of undervalued high-return companies.
Although the name sounds like an insurance company, United-Guardian makes personal and medical lubricants and pharmaceuticals.
The company is earning very high returns on the capital employed in the business, with an earnings yield of over 10%.
The cash dividend yield is 5.6% at the current price.
Although it is not part of the formula, United-Guardian also has a bulletproof balance sheet with plenty of cash and no long-term debt.
The President of United-Guardian owns almost 30% of the company, which has discouraged institutions from buying the stock. Funds currently own just 22% of the company.
We often find high-return companies trading at bargain prices because they are in a business everyone hates.
This is doubly true for Alliance Resource Partners LP (Ticker: ARLP).
This natural resource company mines coal and sells it to utilities and industrial users in the United States.
I would be hard-pressed to think of a business more hated than coal in today&#8217;s world.
Moreover, Alliance Resource Partners is just that: a partnership.
It is a Master Limited Partnership, which means you get a K-1 instead of a 1099 each year for tax purposes.
K-1s are a pain in the backside region.
It is probably worth putting up with the hassle. Alliance Resources earns high returns on capital and generates a ton of cash, most of which ends up in shareholders&#8217; pockets.
The earnings yield is 13%, and the cash dividend yield is 10.25%.
While coal is the dominant business, Alliance also has a growing royalties business. It owns 68,578 net royalty acres in premier oil and gas producing regions that produce over 3 million barrels equivalent of crude and natural gas.
Plenty of skin is in the game as insiders own about 17% of this company.
Most institutional managers would cut off a limb before getting caught with a coal company on their sheets, so ownership by the big funds is just 17%.
On the renewable fuel side of the equation, we find Future Fuel (Ticker: FF), a company that makes fuels from a mix of diesel, vegetable oils, and grease feedstock.
They also have a chemical division that makes products used in everything from farming to dish detergent.
The dividend yield is over 4%, and the earnings yield is over 15%.
Institutions own very little stock apart from index funds.
Insiders, on the other hand, own 41% of Future Fuel.
You may notice that I did not do a &#8220;deep dive&#8221; on any of these companies.
That is the whole idea of formulaic investing.
In the last interview he gave, Ben Graham suggested that most investors would be better served by a value-based formula approach to investing.
He told the Financial Analysts Journal, &#8220;In the old days, any well-trained security analyst could do a good professional job of selecting undervalued issues through detailed studies; but in the light of the enormous amount of research now being carried on, I doubt whether in most cases such extensive efforts will generate sufficiently superior selections to justify their cost.&#8221;
He suggested instead that a formula approach, rigidly followed, would likely deliver market-beating results with a minimum of effort. Who are we to argue with Ben?

Opinion

ARLP

Under the Radar: Maximize Returns with Time-Tested Investment Formulas

Trump's first day in office brought a wave of executive orders targeting immigration, energy, social policies, and announcing the withdrawal from global agreements like the Paris Climate Accord and <a href="https://www.benzinga.com/topic/donald-trump">the World Health Organization. </a>
Trump also pledged to raise tariffs up to 25% on both Canada and Mexico starting Feb. 1, but fell short of announcing universal tariffs on all imports.
Following Monday&#8217;s market closure for Martin Luther King Jr. Day, investors began assessing how Trump's new policy measures could impact sectors across the board. 
Gold miners and defense stocks outperformed, while solar energy companies were among the hardest hit.
<h3 class="wp-block-heading">Wall Street&#8217;s Winners And Losers After Trump&#8217;s Day 1</h3>
Gold miners were among the standout performers, amid rising trade fears between the U.S. and Canada. 
The VanEck Gold Miners ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GDX#NYSE">GDX</a>) climbed 2.6% by 1:30 p.m. ET Tuesday. Leading gains were Harmony Gold Mining Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HMY#NYSE">HMY</a>), up 4.3% and Endeavour Silver Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EXK#NYSE">EXK</a>), up 3.1%.
&#8220;While President Trump's Inauguration Day policy announcements on tariffs were more benign than expected, we continue to expect the White House to increase tariff rates on autos and imports from China, and we see other tariff proposals as a risk,&#8221; Goldman Sach&#8217;s analyst Elsie Peng wrote in a note Tuesday.
Defense stocks also surged as Trump's policies emphasized national security and border protection declaring a &#8220;national emergency&#8221; at the southern border with Mexico. The iShares U.S. Aerospace &amp; Defense ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ITA#NYSE">ITA</a>) rose 3.3%.
Other notable movers included the U.S. Global Jets ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JETS#NYSE">JETS</a>), up 2%, and the SPDR S&amp;P Metals &amp; Mining ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XME#NYSE">XME</a>), which rose 1.6% as investors bet on increased demand for industrial materials.
Oil and gas exploration companies saw declines despite <a href="https://www.benzinga.com/government/regulations/25/01/43097430/trumps-drill-baby-drill-era-begins-oil-prices-tumble-us-energy-stocks-edge-up">Trump's "Drill, Baby, Drill"</a> push to unleash U.S. energy resources. The SPDR S&amp;P Oil &amp; Gas Exploration &amp; Production ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOP#NYSE">XOP</a>) dropped 1.1%, signaling concerns about potential oversupply.
Clean energy and solar stocks, however, suffered from Trump's decision to halt offshore wind leasing and withdraw the U.S. from the Paris Climate Accord. 
The Invesco Solar ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAN#NYSE">TAN</a>) fell 3.1%, with losses from Daqo New Energy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DQ#NYSE">DQ</a>), down 6.7%, and First Solar Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>), which dropped 5.4%. The Invesco WilderHill Clean Energy ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PBW#NYSE">PBW</a>) slipped 1%.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43103527/mexican-peso-canadian-dollar-slide-as-trump-threatens-25-tariffs-expert-eyes-price-hikes-on-typical-us-breakfast">Mexican Peso, Canadian Dollar Slide As Trump Threatens 25% Tariffs, Economist Eyes Price Hikes On &#8216;Typical US Breakfast&#8217;</a></li>
</ul>
Photo: Shutterstock

Government

Large Cap

Mid Cap

Regulations

Sector ETFs

Econ #s

FSLR

Market Vectors ETF Trust Market Vectors Gold Miners

iShares Dow Jones US Aerospace & Defense Index Fund

JETS

PowerShares Exchange Traded Fund Trust WilderHill Clean Energy Portfolio

Trump's First Day Sends Gold Miners, Defense Stocks Soaring, Solar Sliding

Scotiabank analyst Patrick Colville maintains MongoDB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>) with a Sector Perform and lowers the price target from $350 to $275.

Scotiabank Maintains Sector Perform on MongoDB, Lowers Price Target to $275

Analyst Terence Flynn of Morgan Stanley maintained a Buy rating on Intellia Therapeutics (NTLA – Research Report), retaining the price target of $5...

Strategic Focus and Financial Resilience: Terence Flynn's Positive Outlook on Intellia Therapeutics

Leerink Partners analyst Mani Foroohar maintained a Buy rating on Intellia Therapeutics (NTLA – Research Report) on January 10 and set a price targ...

Intellia Therapeutics' Strategic Reorganization and Promising Clinical Progress Justify Buy Rating

Oppenheimer lowered the firm's price target on Intellia Therapeutics (NTLA) to $40 from $60 and keeps an Outperform rating on the shares after mana...

Intellia Therapeutics price target lowered to $40 from $60 at Oppenheimer

Intellia Therapeutics: Buying The Path To Commercialization

After having hosted Intellia Therapeutics (NTLA)' CEO John Leonard at the firm's healthcare conference, JPMorgan said management "shed light" on th...

Intellia ATTR, HAE studies progressing as planned, says JPMorgan

J.P. Morgan analyst Brian Cheng has maintained their bullish stance on NTLA stock, giving a Buy rating today. Brian Cheng has given his Buy rating ...

Intellia Therapeutics: Strategic Initiatives and Clinical Progress Justify Buy Rating

In a report released today, Alec Stranahan from Bank of America Securities maintained a Buy rating on Intellia Therapeutics (NTLA – Research Report...

Intellia Therapeutics (NTLA) Receives a Buy from Bank of America Securities

Intellia Therapeutics Disappointed Investors Again On January 9 (Rating Downgrade)

CRISPR Therapeutics: Unfairly Punished By The Issues Of Its Peers

Editas And Intellia: Strategic Shifts And Long-Term Investment Potential

EDIT

VRTX

Press Releases

Intellia Therapeutics Announces New Date for Upcoming Investor Webcast

Intellia Presents Positive Results from the Phase 2 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)

Intellia Therapeutics Announces Two Upcoming Investor Events in November 2024

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Earnings

Intellia Therapeutics Announces Third Quarter 2024 Financial Results and Highlights Recent Company Progress

Intellia Announces First Clinical Evidence from Ongoing Phase 1 Study that Nexiguran Ziclumeran (nex-z), an In Vivo CRISPR/Cas9-Based Gene Editing Therapy, May Favorably Impact Disease Progression in Transthyretin (ATTR) Amyloidosis

Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy

Intellia Therapeutics Announces Anticipated 2025 Milestones and Strategic Reorganization to Prioritize the Advancement of its Late-Stage Programs, NTLA-2002 and Nexiguran Ziclumeran (nex-z)

Comments

Intellia Therapeutics

Intellia Therapeutics (NTLA) 옵션

Intellia Therapeutics (NASDAQ:NTLA) 주식, 옵션 체인

뉴스

파트너 / 기고자

벤징가 글로벌